Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immune Infiltration and N(6)-Methyladenosine ncRNA Isoform Detection in Acute Lung Injury. | J Oncol | 2022 | 35813860 | PubTator, text mining | PubMed |
| Role of m6A modification in female infertility and reproductive system diseases. | Int J Biol Sci | 2022 | 35813486 | PubTator, text mining | PubMed |
| N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma. | Front Cell Dev Biol | 2022 | 35813200 | PubTator, text mining | PubMed |
| m6A Regulator-Mediated RNA Methylation Modification Patterns Regulate the Immune Microenvironment in Osteoarthritis. | Front Genet | 2022 | 35812736 | PubTator, text mining | PubMed |
| Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma. | Front Immunol | 2022 | 35812416 | PubTator, text mining | PubMed |
| The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model. | Toxicol In Vitro | 2022 | 35811015 | PubTator, text mining | PubMed |
| METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. | EBioMedicine | 2022 | 35810559 | PubTator, text mining | PubMed |
| Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer. | Cancers (Basel) | 2022 | 35804965 | PubTator, text mining | PubMed |
| TRIM24 is an insulin-responsive regulator of P-bodies. | Nat Commun | 2022 | 35803934 | PubTator, text mining | PubMed |
| A paediatric dysembryoplastic neuroepithelial tumour (DNET) with deregulated stem cell markers: a case report. | Transl Pediatr | 2022 | 35800288 | PubTator, text mining | PubMed |
| Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration. | J Oncol | 2022 | 35799606 | PubTator, text mining | PubMed |
| Progress and application of epitranscriptomic m6A modification in gastric cancer. | RNA Biol | 2022 | 35796515 | PubTator, text mining | PubMed |
| Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. | J Hematol Oncol | 2022 | 35794625 | PubTator, text mining | PubMed |
| Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types. | Exp Mol Med | 2022 | 35794212 | PubTator, text mining | PubMed |
| The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research. | Front Pharmacol | 2022 | 35784761 | PubTator, text mining | PubMed |
| Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of β-catenin by promoting δ-catenin ubiquitin degradation and upregulating SIK1. | Mol Cancer | 2022 | 35780119 | PubTator, text mining | PubMed |
| N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients. | BMC Cancer | 2022 | 35778697 | PubTator, text mining | PubMed |
| The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer. | Medicine (Baltimore) | 2022 | 35777046 | PubTator, text mining | PubMed |
| C16orf72/HAPSTR1 is a molecular rheostat in an integrated network of stress response pathways. | Proc Natl Acad Sci U S A | 2022 | 35776542 | PubTator, text mining | PubMed |
| Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer. | Dis Markers | 2022 | 35774851 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=60